However, aromatase inhibitors (AIs), the standard treatment for the majority of postmenopausal women with estrogen receptor-positive breast cancer, increase bone loss at twice the rate that occurs physiologically and exacerbates the risk of fragility fractures [3]. Here, CYP19A1 is linked to breast carcinoma.